Volume : 13, Issue : 01, January – 2026
Title:
DEVELOPMENT AND CHARACTERIZATION OF TRASTUZUMAB ETHOSOMAL DRUG DELIVERY SYSTEM
Authors :
Mudeli Sai Kerthi*, Dr. P. Sobitha rani
Abstract :
Trastuzumab‐loaded ethosomes were developed and characterized to enhance transdermal delivery and provide controlled drug release. Eight formulations containing varying concentrations of lipid were prepared and evaluated for Preformulation parameters, vesicle characteristics, in vitro release behavior and stability. Trastuzumab was identified as a white to off-white, tasteless and odorless crystalline powder with a melting point of 70–80 °C and good aqueous solubility. FT-IR studies confirmed the absence of drug–excipient interactions. The ethosomal vesicles exhibited spherical morphology with particle sizes ranging from 186 nm to 253 nm and a negative zeta potential (–23 mV to –30 mV), indicating good colloidal stability. Entrapment efficiency was high (76.86 %–85.10 %), with formulation F8 showing the highest value and achieving 97.98 % cumulative drug release within 12 h. Drug-release kinetics for the optimized formulation followed Higuchi’s diffusion model (R² = 0.973). Accelerated stability testing (40 ± 2 °C/75 ± 5 % RH for 3 months) revealed no significant loss of drug content, which remained above 94 %. The results demonstrate that ethosomes can effectively encapsulate trastuzumab and provide a stable, sustained-release transdermal delivery system suitable for further therapeutic development.
Keywords: Trastuzumab, Ethosomes, FTIR Studies, In vitro drug release studies, Stability studies
Cite This Article:
Please cite this article in press Mudeli Sai Kerthi et al., Development And Characterization Of Trastuzumab Ethosomal Drug Delivery System, Indo Am. J. P. Sci, 2026; 13(01).
REFERENCES:
1. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160.
2. Touitou, E., Dayan, N., Bergelson, L., Godin, B., &Eliaz, M. (2000). Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release, 65(3), 403–418.
3. Touitou, E., Godin, B., & Weiss, C. (2006). Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Development Research, 67(5), 321–329.
4. Bendas, E. R., &Tadros, M. I. (2007). Enhanced transdermal delivery of salbutamol sulfate via ethosomes. AAPS PharmSciTech, 8(4), E1–E7.
5. Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 9(7), 463–475.
6. Hudis, C. A. (2007). Trastuzumab—mechanism of action and use in clinical practice. New England Journal of Medicine, 357(1), 39–51.
7. Slamon, D. J., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer. New England Journal of Medicine, 344(11), 783–792.
8. Patel, D., Patel, J., & Patel, C. (2013). Ethosomes: a promising tool for transdermal delivery of drugs. Journal of Pharmacy Research, 6(3), 321–328.
9. Mishra, B., Patel, B. B., & Tiwari, S. (2010). Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine: Nanotechnology, Biology and Medicine, 6(1), 9–24.
10. Allen, T. M., &Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48.
11. Dong YD, Larson I, Hanley T and Boyd BJ: Bulk and dispersed aqueous phase behavior of phytantriol: Effect of vitamin E acetate and F127 polymer on liquid crystal nanostructure. Langmuir 2006; 22: 9512-18.
12. Zhai J: Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. ACS Appl. Mater. Interfaces 2018; 10: 25174-85.
13. Salentinig S, Yaghmur A, Guillot S and Glatter O: Preparation of highly concentrated nanostructured dispersions of controlled size. J Colloid InterfSci 2008; 306: 211-20. 67.
14. Shah MH, Biradar SV and Paradkar AR: Spray dried glyceryl monooleate-magnesium trisilicate dry powder as cubic phase precursor. Int J Pharm 2006; 323: 18-26.
15. Bei D, Meng J and Youan BB: Engineering nanomedicines for improved melanoma therapy: progress and promices. Nanomedicine 2010; 5: 1385-99.
16. Urvi S, Dhiren D, Bhavin P, Patel U and Shah R: Overview of Cubosomes: A Nano Particle. International Journal of Pharmacy and Integrated Life Sciences 2013; 1(5): 36-47.